Equity Overview
Price & Market Data
Price: $2.36
Daily Change: +$0.01 / 0.42%
Daily Range: $2.20 - $2.50
Market Cap: $799,617,728
Daily Volume: 4,844,229
Performance Metrics
1 Week: -0.85%
1 Month: -1.27%
3 Months: 14.71%
6 Months: -4.49%
1 Year: -26.42%
YTD: -12.03%
Company Details
Employees: 220
Sector: Health technology
Industry: Biotechnology
Country:
Details
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.